Sanyou AI-STAL 2.0 Revolutionizes Antibody Discovery with Unmatched Speed Sanyou Bio's AI-STAL 2.0 offers a groundbreaking 14-day workflow for rapid antibody discovery, integrating advanced AI technologies and molecular libraries to enhance drug R&D.

Sanyou AI-STAL 2.0 Revolutionizes Antibody Discovery with Unmatched Speed #China #Shanghai #Sanyou_Bio #Antibody_Discovery #AI-STAL_2.0

Robert Hollingsworth Takes the Helm as Chief Scientific Officer at Protillion Biosciences Protillion Biosciences has appointed Robert Hollingsworth as their new Chief Scientific Officer, advancing their innovative antibody discovery platform.

Robert Hollingsworth Takes the Helm as Chief Scientific Officer at Protillion Biosciences #United_States #Carlsbad #Antibody_Discovery #Protillion_Biosciences #Robert_Hollingsworth

Adimab Achieves Significant Growth in Clinical Programs for 2025 Adimab has reported impressive growth in its clinical programs, launching 11 new initiatives in 2025 and achieving notable market approvals.

Adimab Achieves Significant Growth in Clinical Programs for 2025 #USA #Clinical_Trials #Lebanon,_NH #Antibody_Discovery #Adimab

Nona Biosciences and Pfizer Join Forces to Enhance Antibody Discovery Process Nona Biosciences has partnered with Pfizer to boost the antibody discovery process using Nona’s advanced human HCAb platform for various diseases.

Nona Biosciences and Pfizer Join Forces to Enhance Antibody Discovery Process #USA #Cambridge,_Massachusetts #Nona_Biosciences #Pfizer #Antibody_Discovery

Antibody Discovery Market Expected to Surge to $3.54 Billion by 2030 Driven by Innovation The global antibody discovery services market is projected to reach $3.54 billion by 2030, growing at a CAGR of 13.3%. Key drivers include advanced technologies and AI integration.

Antibody Discovery Market Expected to Surge to $3.54 Billion by 2030 Driven by Innovation #United_States #Delray_Beach #Monoclonal_Antibodies #Bispecific_Antibodies #Antibody_Discovery

Strategic Alliance Formed Between Harbour BioMed and Insilico Medicine to Propel AI-Driven Antibody Innovations Harbour BioMed and Insilico Medicine have joined forces to enhance antibody discovery using cutting-edge AI technology, aiming for groundbreaking medical advancements.

Strategic Alliance Formed Between Harbour BioMed and Insilico Medicine to Propel AI-Driven Antibody Innovations #None #Insilico_Medicine #Harbour_BioMed #Antibody_Discovery